JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

Kodu・Aktsiate loetelu・Denali Therapeutics Inc

Denali Therapeutics Inc

Suletud

SektorTervishoid

19.91 -6.22

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

19.73

Max

21.32

Põhinäitajad
By Trading Economics
Sissetulek	-2.8M -127M
Töötajad	517
EBITDA	-12M -134M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+55.08% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	25. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	1.3B 3.6B
Eelmine avamishind	26.13
Eelmine sulgemishind	19.91

Uudiste sentiment

By Acuity

63%

37%

307 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

13.355 / 16.44 Toetus ja vastupanu

Denali Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. veebr 2026, 23:57 UTC

Tulu

Naver Has Record Year Despite Weaker Final Quarter

5. veebr 2026, 23:45 UTC

Kuumad aktsiad

Stocks to Watch: Amazon, Coty, Gen Digital, Roblox

5. veebr 2026, 22:26 UTC

Tulu

REA Group Lifts Dividend, Announces Buyback as 1st Half Profit Rises 9% -- Update

5. veebr 2026, 22:00 UTC

Tulu

REA Group Lifts Dividend, Announces Buyback as 1st Half Profit Rises 9%

5. veebr 2026, 23:47 UTC

Market Talk

Global Equities Roundup: Market Talk

5. veebr 2026, 23:47 UTC

Market Talk

Nikkei May Fall After U.S. Tech Stock Drops -- Market Talk

5. veebr 2026, 23:43 UTC

Market Talk

Gold Falls on Spillover Impact From Cryptocurrencies' Selloff -- Market Talk

5. veebr 2026, 23:37 UTC

Market Talk

Glencore Shares Look Cheap After Failed Takeover Talks -- Market Talk

5. veebr 2026, 23:20 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Amazon to Spend $200 Billion as It Accelerates AI Projects -- 5th Update

5. veebr 2026, 23:11 UTC

Market Talk

Amazon CEO Confident in Return on $200B Investment -- Market Talk

5. veebr 2026, 23:09 UTC

Tulu

Naver 2025 Net KRW1.820T Vs. Net KRW1.932T >035420.SE

5. veebr 2026, 23:08 UTC

Tulu

Naver 2025 Oper Pft KRW2.208T Vs. Pft KRW1.979T >035420.SE

5. veebr 2026, 23:07 UTC

Tulu

Naver 2025 Rev KRW12.035T Vs. KRW10.738T >035420.SE

5. veebr 2026, 23:03 UTC

Market Talk

Tulu

REA's Update Looks Negative Despite A$200M Buyback -- Market Talk

5. veebr 2026, 23:03 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Bitcoin Booster's $12 Billion Loss Headlines Crypto's Worst Day Since 2022 Crash -- WSJ

5. veebr 2026, 23:00 UTC

Tulu

Naver 4Q Net Profit Missed FactSet-Compiled Consensus

5. veebr 2026, 23:00 UTC

Tulu

Naver 4Q Net KRW164.60B Vs. Net KRW514.00B >035420.SE

5. veebr 2026, 22:59 UTC

Tulu

Naver 4Q Oper Pft KRW610.60B Vs. Pft KRW542.00B >035420.SE

5. veebr 2026, 22:59 UTC

Tulu

Naver 4Q Rev KRW3.195T Vs. KRW2.886T >035420.SE

5. veebr 2026, 22:52 UTC

Tulu

Alphabet Stock Is Taking a Hit After Strong Earnings. Don't Panic. -- Barrons.com

5. veebr 2026, 22:45 UTC

Tulu

Amazon Stock Falls Sharply on Earnings. Spending Continues to Soar. -- Barrons.com

5. veebr 2026, 22:37 UTC

Market Talk

Woolworths's Profit Margin Likely Faces 2Q Squeeze -- Market Talk

5. veebr 2026, 22:11 UTC

Tulu

REA Group Lifts Dividend, Announces Buyback as 1H Profit Rises 9% -- Update

5. veebr 2026, 22:03 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Amazon to Spend $200 Billion as It Accelerates AI Projects -- 4th Update

5. veebr 2026, 22:01 UTC

Tulu

Reddit Stock Jumps on Earnings. CFO Cites Modest AI Spending. -- Barrons.com

5. veebr 2026, 21:59 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

What's Next For Rio Tinto, Glencore After Deal Talks Fail? -- Market Talk

5. veebr 2026, 21:51 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Saylor's Strategy Posts $12 Billion Quarterly Loss on Bitcoin Selloff -- WSJ

5. veebr 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Basic Materials Roundup: Market Talk

5. veebr 2026, 21:49 UTC

Tulu

Why Google's Bad News Was Good News for Broadcom and Nvidia -- Barrons.com

5. veebr 2026, 21:45 UTC

Tulu

REA Group Lifts Dividend, Announces Buyback as 1H Profit Rises 9%

Võrdlus sarnastega

Hinnamuutus

Denali Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

55.08% tõus

12 kuu keskmine prognoos

Keskmine 33 USD 55.08%

Kõrge 40 USD

Madal 25 USD

Põhineb 12 Wall Streeti analüütiku instrumendi Denali Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

12 ratings

Osta

Hoia

Müü

Põhineb 12 analüütiku instrumendi Denali Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

13.355 / 16.44Toetus ja vastupanu

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bearish.

Sentiment

By Acuity

307 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.